Google AI


The Times

.

Zuellig Pharma and Institut AllergoSan sign 10-year regional partnership to bring leading probiotic brand OMNi-BiOTiC® to key markets in Asia

New agreement marks major milestone for Zuellig Pharma as it focuses on expanding its consumer healthcare segment, and for Institut AllergoSan as it expands its global presence

SINGAPORE - Media OutReach Newswire - 19 July 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has signed a 10-year commercialisation partnership with Austria-based Institut AllergoSan, a research and development company that specialises in products made from natural substances such as probiotic bacteria, plant extracts and minerals.

More Articles …

  1. Luxury Skincare J. Bruhin Muller Announces Launch of New Imperial Rose Collection
  2. OxPay on the Verge of Adding Potentially Lucrative Business: Issuing Credit Cards
  3. Laura Ellington Music’s "Shining Star Amid The Straits" Captures Singapore’s Spirit
  4. "Bring In The Wine" — Fusing Poetry and Colours SHANGHAI TANG Unveils 2024 Autumn-Winter Collection
  5. The Corporate Engine Powering VinFast's Global Push
  6. Online Rich Celebrates Its Fifth Anniversary, Achieving New Milestones in the Asian Market and Assisting Over 2100 Entrepreneurs in Achieving Success
  7. Servier earns the Best Place to Work certification in Hungary for 2024
  8. VinFast delivers first batch of VF e34 in Indonesia
  9. MEET48's New Generation AI Creation Tool SRMBuildor Drives the Transformation of the Idol Industry
  10. HKSTP Congratulates Record-breaking 641 Units of Graduates Comprehensive Support at Every Stage Fuels Start-Ups’ Global Aspirations